Cost-Effectiveness of Magnetic Resonance Imaging with a New Contrast Agent for the Early Diagnosis of Alzheimer's Disease
Authors:
Open Access
- 20 April 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (4) , e35559
Abstract
Used as contrast agents for brain magnetic resonance imaging (MRI), markers for beta-amyloid deposits might allow early diagnosis of Alzheimer's disease (AD). We evaluated the cost-effectiveness of such a diagnostic test, MRI+CLP (contrastophore-linker-pharmacophore), should it become clinically available. We compared the cost-effectiveness of MRI+CLP to that of standard diagnosis using currently available cognition tests and of standard MRI, and investigated the impact of a hypothetical treatment efficient in early AD. The primary analysis was based on the current French context for 70-year-old patients with Mild Cognitive Impairment (MCI). In alternative “screen and treat” scenarios, we analyzed the consequences of systematic screenings of over-60 individuals (either population-wide or restricted to the ApoE4 genotype population). We used a Markov model of AD progression; model parameters, as well as incurred costs and quality-of-life weights in France were taken from the literature. We performed univariate and probabilistic multivariate sensitivity analyses. The base-case preferred strategy was the standard MRI diagnosis strategy. In the primary analysis however, MRI+CLP could become the preferred strategy under a wide array of scenarios involving lower cost and/or higher sensitivity or specificity. By contrast, in the “screen and treat” analyses, the probability of MRI+CLP becoming the preferred strategy remained lower than 5%. It is thought that anti-beta-amyloid compounds might halt the development of dementia in early stage patients. This study suggests that, even should such treatments become available, systematically screening the over-60 population for AD would only become cost-effective with highly specific tests able to diagnose early stages of the disease. However, offering a new diagnostic test based on beta-amyloid markers to elderly patients with MCI might prove cost-effective.Keywords
This publication has 46 references indexed in Scilit:
- APOE and Alzheimer disease: a major gene with semi-dominant inheritanceMolecular Psychiatry, 2011
- Diagnosis and biomarkers of predementia in Alzheimer's diseaseBMC Medicine, 2010
- Modeling screening, prevention, and delaying of Alzheimer's disease: an early-stage decision analytic modelBMC Medical Informatics and Decision Making, 2010
- Amyloid load in nondemented brains correlates with APOE e4Neuroscience Letters, 2010
- Enhancing Caregiver Health: Findings from the Resources for Enhancing Alzheimer's Caregiver Health II InterventionJournal of the American Geriatrics Society, 2010
- Amyloid imaging in mild cognitive impairment subtypesAnnals of Neurology, 2009
- Episodic memory loss is related to hippocampal-mediated -amyloid deposition in elderly subjectsBrain, 2008
- Long-term Course and Effectiveness of Combination Therapy in Alzheimer DiseaseAlzheimer Disease & Associated Disorders, 2008
- Global prevalence of dementia: a Delphi consensus studyThe Lancet, 2005
- Genetic associations with human longevity at the APOE and ACE lociNature Genetics, 1994